Lectenz Bio, Inc.
Athens, GA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 111 Riverbend Rd, Athens, GA 30602, USA
- Website
- lectenz.com
- Founded
- 2007
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of research reagents specific for O-glcnac (O-glcnac lectenz) | National Cancer Institute (NIH) | $999,970 | |
| Sbir topic 294 phase 1 - development of glycosylation - specific research | National Cancer Institute (NIH) | $148,851 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Lectenz Bio, Inc., registered in SAM.gov since December 2007, is a for-profit corporate entity located in Athens, Georgia, specializing in biotechnology research and development focused on glycan-specific reagents and advanced analytical technologies. The company develops innovative tools and techniques for detecting and analyzing glycans, which are complex carbohydrate structures critical in understanding biological processes and disease markers. Their core technological approach involves engineering glycan-processing enzymes and glycan-binding proteins into high-affinity, specialized reagents with adaptable properties.
The company has secured multiple federal grants from prominent agencies including the National Institute of General Medical Sciences (NIGMS) and the Office of the Director, primarily through Project Grant awards in the Biomedical Research and Research Training program (CFDA 93.859). Their recent grant-funded projects have concentrated on developing advanced glycosylation monitoring technologies, such as the GlycoSense™ platform for tracking protein glycosylation during therapeutic biologics production and engineered reagents for detecting specific glycan structures. Specifically, Lectenz Bio has been working on creating pan-specific N-glycan binding reagents, developing high-affinity "Lectenz" reagents for cancer biomarker detection, and creating innovative flow cytometry-based methods for monitoring glycosylation patterns. These projects aim to provide researchers and pharmaceutical developers with more precise, efficient tools for glycan analysis, with potential applications in disease detection, biomarker research, and therapeutic production quality control.
Quick answers
Is Lectenz Bio, Inc. registered in SAM.gov?
Yes. Lectenz Bio, Inc.'s SAM.gov registration is active through September 15, 2027.
What is Lectenz Bio, Inc.'s CAGE code?
Lectenz Bio, Inc.'s CAGE code is 4XHN3, and its Unique Entity ID (UEI) is JTGCK219C6F4.
What is Lectenz Bio, Inc.'s most recent federal award?
Lectenz Bio, Inc.'s most recent federal grant award is Innovative glycan-specific reagents to accelerate the detection of disease biomarkers (R44GM159548), from National Institute of General Medical Sciences (NIH), on July 18, 2025.
On GovTribe
See Lectenz Bio, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors